Teprotumumab in advanced reactivated thyroid eye disease

PURPOSE: To report the case of a patient with reactivated, refractory thyroid eye disease (TED) treated with teprotumumab. OBSERVATIONS: A 51-year-old female with a 16-year history of thyroid eye disease previously treated with orbital decompression and multiple eyelid surgeries presented in a recur...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Olivia T., Schlachter, Dianne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935537/
https://www.ncbi.nlm.nih.gov/pubmed/35321251
http://dx.doi.org/10.1016/j.ajoc.2022.101484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935537/
https://www.ncbi.nlm.nih.gov/pubmed/35321251
http://dx.doi.org/10.1016/j.ajoc.2022.101484

Ejemplares similares